Injective Price Rises on ETF Listing Plans and Phantom Integration

Injective's price surged by over 17% in recent market fluctuations. The increase is attributed to several developments within the Injective ecosystem, primarily driven by the proposed ETF listing with 21Shares and the wallet integration with Phantom.

The proposed ETF plans to allocate between 40% and 60% of its INJ holdings for staking purposes, which can generate additional yield while maintaining flexibility around liquidity management. The ETF is expected to list on Nasdaq under the ticker TINJ, with the FTSE Injective Index serving as its pricing benchmark.

The integration with Phantom allows users to hold, trade, borrow, and exchange tokens through the wallet's application and web extension, providing a more direct route for interactions with the Injective network. This expansion in accessibility is expected to enhance user adoption and participation within the ecosystem.